Research Analysts Issue Forecasts for ETON Q2 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for Eton Pharmaceuticals in a report released on Monday, January 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.08 for the quarter, up from their prior estimate of $0.07. HC Wainwright currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2025 earnings at $0.38 EPS and FY2026 earnings at $0.84 EPS.

Separately, Craig Hallum boosted their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday.

Eton Pharmaceuticals Price Performance

NASDAQ:ETON opened at $12.01 on Thursday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $15.00. The business has a 50 day moving average of $11.57 and a 200 day moving average of $7.32. The company has a market capitalization of $312.87 million, a price-to-earnings ratio of -54.59 and a beta of 1.38.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wasatch Advisors LP bought a new stake in Eton Pharmaceuticals during the 3rd quarter valued at approximately $1,431,000. Thompson Siegel & Walmsley LLC purchased a new position in shares of Eton Pharmaceuticals in the second quarter worth $420,000. Aristides Capital LLC bought a new position in shares of Eton Pharmaceuticals during the second quarter worth $658,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after acquiring an additional 30,167 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares in the last quarter. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.